Replies to post #4598 on RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

So you are suggesting that, based on a theoretical hypothesis by Gary Lynch, that Servier can take unsafe high impact drugs, and figure out how often to dose human subjects in order to walk the tightrope between neurotrophin upregulation and side effects like seizures, ataxia, or whatever else they have come up against. Wow.

<<Anyway, this may open the door wide open for AMPA upmodulators that wouldn't have previously been viable.>>

I don't think so. Half life has not been the issue with Lilly's past generations, or S18986....it's safety.

Keep in mind that the contractual raison d'etre behind the Servier funded work at Cortex was to identify Ampakines that might be useful in anxiety. I'm not real worried that the efforts to 'tune' Ampakines in that direction will have produced compounds that, given at some unknown infrequency of administration, will effectively and safely treat Alzheimer's or PD.

NeuroInvestment